In the study of more than 1,000 patients with ALS seen between 2012 and mid-2024, people from the most disadvantaged neighborhoods had up to a 37% shorter survival time compared to those from the ...

The analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs.

The researchers also identified a level of neurofilament light chain protein that can help predict survival for people with ALS. Within a year, more than 40% of people with protein levels below ...

The analyses further substantiate that treatment with CNM-Au8 ® 30 mg delivers a significant survival benefit for people living with ALS. New Survival Analyses The analyses compared survival in ...

Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc ...

Advertisement A blood test looking for neurofilament light chain proteins accurately identified ALS patients more than 80% of the time, researchers said. The test also can help predict survival ...

The analyses further substantiate that treatment with CNM-Au8 ® 30 mg delivers a significant survival benefit for people living with ALS. New Survival Analyses The analyses compared survival in ...